Hematological, Inflammatory, and Novel Biomarkers Assessment as an Eminent Strategy for Clinical Management of Covid-19

Background: Different biomarkers have been suggested as novel markers of coronavirus disease 2019 (COVID-19) severity. We aimed to determine the correlation between acute respiratory syndrome coronavirus-2 (SARS-CoV-2) immunoglobulin M (IgM) and IgG antibodies and hematologic, inflammatory, and novel biomarkers for better clinical management of COVID-19.Methods: Blood samples from 127 confirmed COVID-19 patients aged 11–84 years old were collected and tested for the levels of SARS-CoV-2 IgM and IgG antibodies alongside with hematologic, inflammatory, and novel biomarkers. The Spearman correlation test was utilized to analyze the correlation between the biomarkers with SARS-CoV-2 IgM and IgG antibodies.Results: The SARS-CoV-2 IgM antibody significantly correlated with erythrocyte sedimentation rate (ESR (r = 0.329, p = 0.000), ), C-reactive protein (CRP) (r = 0.459, p=0.000), interleukin (IL)-6 (r = 0.345, p=0.000), IL-8 (r = 0.263, p = 0.003), neutrophil to lymphocyte ratio (NLR) (r = 0.182, p = 0.040), derived NLR (dNLR) (r = 0.197, p = 0.026,) , neutrophil to monocyte ratio (NMR) (r = 0.184, p= 0.038) and CRP to lymphocyte ratio (CLR) (r = 0.495, p = 0.000). Also, we find significant correlation between SARS-CoV-2 IgG antibody with hemoglobin (Hb) (r = -0.257, p = 0.004), hematocrit (Hct) (r = -0.227, p = 0.010), mean corpuscular Hb concentration (MCHC) (r = -0.212, p=0.017), lymphocyte count (r = -0.211, p= 0.017), platelet count (r = 0.179, p = 0.044), ESR (r = 0.461, p = 0.000) CRP (r = 0.344, p = 0.000), IL-6 (r = 0.178, p=0.046); IL-8(r = 0.237, p = 0.007), platelet to lymphocyte ratio (PLR) (r = 0.295, p = 0.001) and CLR (r = 0.376, p = 0.000).Conclusion: Hematologic (Hb, Hct, MCHC, lymphocyte and platelet counts, inflammatory (ESR, CRP, IL-6, and IL-80), and novel biomarkers (dNLR, NLR, NMR, PLR and CLR) are suitable indicators for quickly and accurately clinical management of COVID-19